Myeloproliferative disorders and myelodysplastic syndromes arise in multipotent progenitors and may be associated with chromosomal deletions that can be detected in peripheral blood granulocytes. We present here seven patients with myeloproliferative disorders or myelodysplastic syndromes in whom a deletion of the long arm of chromosome 20 was detectable by G-banding andlor fluorescence in situ hybridization in most or all bone marrow metaphases. However, in each case, microsatellie polymerase chain reaction (PCR) using 15 primer pairs spanning the common deleted region on 20q showed that the deletion was absent from most peripheral blood granulocytes. The human androgen receptor c l o n a l i assay was used to show that the vast majority of peripheral blood granulocytes were clonal in all four female patients. This represents the first demonstration YELOPROLIFERATIVE disorders (MPD) and myelodysplastic syndromes (MDS) represent an overlapping spectrum of clonal preleukemic conditions.'s Both categories of disease are thought to reflect the acquisition of mutations by multipotent progenitors, the dysregulation of which results in disordered hematopoiesis. Chromosome rearrangements frequently flag the sites of target genes altered during the genesis of hematologic malignancies. In acute leukemia, chromosome translocations often lead to structural alterations of critical genes3 By contrast, chromosome deletions and other quantitative abnormalities are the most prevalent cytogenetic aberrations in patients with MPD or MDS!-7
Deletions of chromosome 20q have been reported in 10% to 15% of patients with polycythemia rubra vera (PRV)*-" and in a variable number of patients with idiopathic myelofibrosis or other MPD.I2 Although more common in the MPDs, 20q deletions are also found in approximately 5% of patients with MDS and in some patients with acute myeloid le~kernia:'~ but only rarely in association with lymphoid malignan~ies.~.~ Because 20q deletions are associated with "stem cell" disorders, we have speculated that they may mark the site of one or more genes, loss or inactivation of which perturbs the behavior of multipotent hematopoietic progenitors.14. '5 Peripheral blood granulocytes are frequently derived from the malignant clone in patients with MDSI6-" or MPD?2-25 Because the abnormal progenitors often dominate hematopoiesis, peripheral blood granulocytes frequently appear to be completely derived from the malignant clone. Granulocyte DNA therefore provides a valuable and accessible source of DNA from the neoplastic clone. Indeed, Southern blotting'9326 and microsatellite polymerase chain reaction (PCR)'5.27,28 have both been used to show the presence of chromosome 5,7, or 20 deletions in peripheral blood leukocytes or purified granulocytes.
The relationship of chromosome deletions to the malignant clone remains unclear. Previous studies have reported that 5q deletions can be detected in peripheral blood granulo- that the 20q deletion can arise as a second event in patients with pre-existing clonal granulopoiesis. Microsatellie PCR analysis of whole bone marrow from two patients was consistent with cytogenetic studies, a result that suggests that cytogenetic analysis was not merely selecting for a minor subclone of cells carrying the deletion. Furthermore, in one patient, the deletion was present in both erythroid and granulocytelmonocyte colonies. This implies that the absence of the deletion in most peripheral blood granulocytes did not reflect lineage restriction of the progenitors carrying the deletion but may instead result from other selective influences such as preferential retentionldestruction within the bone marrow of granulocytes carrying the deletion. cytes when the deletion is present in all or most bone marrow metaphase^.^^ Moreover, molecular analysis of chromosome 5q deletions in purified blood cell types was completely concordant with clonality studies using X-linked polymorphic markers.'9s27 However, we have previously used Epstein-Barr virus (EBV) transformation to show that the 20q deletion can arise in a multipotent progenitor of both myeloid and B cells.28 Interestingly, the deletion was detectable in highly purified peripheral blood granulocytes but not in B cells. In view of the relatively rapid turnover of most peripheral blood B cells, these observations suggest that the deletion arose in a progenitor able to give rise to granulocytes but with a relatively impaired capacity to produce B cells.
In the light of these observations, we were intrigued to find several patients with 20q deletions that were present in most or all bone marrow metaphases but that were not detectable by microsatellite PCR in purified peripheral blood granulocytes. We report here the detailed analysis of seven such patients. In all seven patients, the 20q deletion was detected in most bone marrow metaphases but was absent The chromosome banding analysis was not performed in Cambridge and data on deletion size were not available.
from the majority of peripheral blood granulocytes. Our results suggest that the most likely explanation for this discrepancy is selective destructionhetention within the bone marrow of granulocytes carrying the 20q deletion. Furthermore, our data represent the first demonstration that the 20q deletion can arise as a secondary event in patients with preexisting clonal granulopoiesis.
MATERIALS AND METHODS

Patients.
Peripheral blood and bone marrow samples from eight patients with myeloid disorders were studied. Both types of sample were obtained at the same time and both were processed within 24 hours of collection. Clinical and cytogenetic details are presented in Table 1 . Four patients presented with MPDs and four patients with MDSs. Diagnoses were established by the referring clinicians. Patient 8 was included as a control because the 20q deletion was readily detectable in her peripheral blood granulocytes.
Cell lines. KS7 is a lymphoblastoid cell line carrying a 20q deletion [46, XY, del(2O)(q11.2-ql3.1)]. KSlO is a cytogenetically normal lymphoblastoid cell line derived from the same patient. Both cell lines were the kind gifts of Dr P. Hollings (Christchurch, New Zealand) and were originally derived from a 37-year-old man with Ph+ acute lymphocytic leukemia (ALL) who developed the 20q deletion after successful remission induction with chemotherapy." Cytogenetic analysis. Metaphase chromosomes were prepared from bone marrow samples after cell synchronization with ethidium bromide (100 mg/mL) and colcemid, using conventional methods. High resolution banding analysis was performed on bromodeoxyuridine (BrdU)-synchronized cell preparations. In each case, metaphase cells were studied from G-banded preparations using Wrights stain.
Preparation of metaphases and cosmid probes forfluorescence in situ hybridization (FISH). Metaphase chromosomes were prepared from bone marrow cultures after cell synchronization with ethidium bromide (100 mg/mL) and colcemid using conventional methods. Chromosome preparations were fixed in methanol/acetic acid (3:1), air-dried, and aged for 5 days at room temperature. They were then incubated with RNAse (100 pg/mL) at 37°C for 1 hour and subsequently washed in 2X sodium saline citrate (SSC) for 5 minutes followed by incubation with pepsin (50 pg/mL at room temperature). The pepsin was inactivated by washing in phosphate-buffered saline (PBS)/50 mmol/L MgCI, for S minutes. The chromosome preparations were subsequently fixed in 1% paraformaldehyde for 10 minutes and dehydrated through an alcohol series. Chromosomal DNA was denatured in situ by incubation in 70% formamide/2x SSC at 72°C for 3 minutes followed by dehydration through an alcohol series.
Cosmids for PLCl, ADA, and PPGB were the kind gifts of Dr Don Bowden (Winston Salem, NC). Cosmid DNA was pEpared from overnight bacterial cultures using standard alkaline lysis methods. The DNA was subsequently incubated at 37°C with RNAse (IO pg/mL) before labeling. Probes were labeled with biotin-l I-dUTP using nick translation (GIBCO BRL, Gaithersburg, MD) and purified through Sephadex-G50 columns. The size of the labeled product was then checked on a 2% agarose gel. Fifty nanograms of cosmid DNA was combined with 2.5 p g Cot-l DNA (GIBCO) and 1.5 pg salmon sperm DNA. The probes were then resuspended in 10 pL hybridization mix (50% formamide, 10% dextran sulphate, 1% Tween, 2X SSC), denatured at 90°C for 5 minutes, chilled on ice for S minutes, and incubated at 37°C for 1 hour to pre-anneal. The a-satellite probe for chromosome 20 was processed according to manufacturers' recommendations (Oncor, Inc, Gaithersburg, MD).
Hybridization and signal detection. Locus probes were cohybridized with the a-satellite probe in a humidified hybridizer overnight at 42°C. Slides were then washed three times in 0.1 X SSC at 60°C and blocked with 3% bovine serum albumin (BSA)/4X SSCTween (SSCT). The biotinylated cosmids were detected using a biotin-avidin-fluoroscein isothiocyanate (FITC) system. The digoxigenin-labeled a-satellite was detected simultaneously using mouse antidigoxigenin followed by rabbit antimouse and goat antirabbittetramethylrhodamine isothiocyanate (TRITC) three-layer system (Sigma, St Louis, MO). Slides were then counterstained with 4'6-diamidino-2 phenylindole dihydrochloride (DAPI; 80 ng/mL) in antifade and viewed using a Cooled Couple Device (CCD) camera (Photometrics, Tucson, AZ) and Smartcapture software (Digital Scientific, Cambridge, UK). Metaphases were scored for the presence or absence of a cosmid signal only when a signal from the centromeric a-satellite probe was present on both chromosome 20 homologues.
PuriJication of peripheral blood granulocytes and T cells. Highly purified granulocyte and T-cell fractions were prepared from peripheral blood using magnetic beads (Dynabeads; Dynal, Oslo, Norway) conjugated to anti-CD15 and anti-CD2 antibodies, respectively. Ten to 20 mL of ethylelene diaminetetra-acetic acid (EDTA)-anticoagulated blood was layered onto Histopaque 1077 cushions (Sigma). Cells from the mononuclear fraction (>83% lymphocytes) were washed in PBS/O.l% BSA and incubated with anti-CD2 conjugated beads according to manufacturer's recommendations. Cells from the granulocyte pellet (>W% granulocytes) were similarly processed with anti-CD15 beads. In each case, the percentage of dynabead-bound cells was determined after each separation procedure using a counting chamber. This was routinely in the range of 90% to 100%. Cells were suspended in distilled, autoclaved water at a concentration of 10s cells/mL, boiled for 5 minutes, and stored at -80°C until required.
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Microsatellite PCR was performed essentially as previously described." Briefly, aliquots of 1,250 dynabeadseparated cells in 12.5 pL of water were amplified in 25 pL of PCR reaction mixtures containing buffer (50 mmoVL KCI, IO mmoVL Tris-HCI, pH 8.3, 1 .S mmol/L MgCI2, 0. I % gelatine), dNTPs (125 pmol/L each), primers (25 pm01 each), and Taq polymerase (0.5 U). In each reaction mixture, 1/10 of one of the primers was end-labeled with "P dATP using polynucleotide kinase. Samples were amplified in an MJ Research programmable thermal controller for 30 cycles (94°C for 40 seconds; annealing temperature for 30 seconds; no extension step) with an initial denaturation (94°C for 5 minutes) and a final extension step (72°C for 15 minutes). Samples were analyzed on 8 mol/L urea, 6% polyacrylamide gels followed by autoradiography. Primer sequences are available from the Genome Data Base (GDB; The Johns Hopkins University, Baltimore, MD). Band densities were calculated using NIH Image Analysis Software version 1.57 (this software is in the public domain).
Microsatellite PCR from bone marrow aspirate slides. Bone marrow aspirate slides were prepared according to conventional methods. After drying, a small area of cells was scraped off using sterile scalpel blades. The scraped material was collected with the aid of 50 pL of sterile PBS and transferred to an Eppendorf tube.
Two hundred microliters of sterile water was added before boiling for 8 minutes in the presence of Cheelex resin (BioRad, Hercules, CA). A total of 12.5pL of the lysate was added to PCR reagent mixes and amplified as outlined above.
Slides were subsequently stained using the May-GriinwaldGiemsa stain. Differential counts performed on 200 nucleated cells were as follows: patient 2, 32% erythroid cells, 62% myeloid cells, and 6% lymphoid cells; patient 3.77% erythroid cells. 20% myeloid cells, and 3% lymphoid cells; and patient 8, 32% erythroid cells, 58% myeloid cells, and 10% lymphoid cells.
Human androgen receptor (HUMARA) clonality assay. Aliquots of 12,500 dynabead-separated cells in 125 pL of water were phenol chloroform extracted and the DNA precipitated using glycogen as carrier. DNA pellets were resuspended in 14 pL of I X Hha I buffer and 40 U of Hha I enzyme added. Hha I is a methylation-sensitive restriction endonuclease. Reactions were left to proceed at 37°C overnight. Digested DNA was then added to a final volume of 25 p L of PCR reaction mixtures at the same concentrations of reagents as for microsatellite PCR reactions (see above). Samples were amplified in an MJ Research programmable thermal controller for 30 cycles (94°C for 40 seconds: 60°C for 30 seconds; and 72°C for 30 seconds) with an initial denaturation (94°C for 5 minutes) and a final extension step (72°C for 15 minutes). Products were analyzed on gels prepared in the same way as for microsatellite PCR products.
Hematopoietic progenitor cell culture. Mononuclear cells from heparin-anticoagulated peripheral blood were isolated by density gradient over Ficoll-Hypaque (density, 1.077 g/mL; Sigma Diagnostics). The resulting interface was harvested and washed twice in Hank's buffered salt solution (HBSS; GIBCO). Fresh viable mononuclear cells were plated in 35-mm Petri dishes (Nunc, Copenhagen, Denmark) in semisolid medium containing 0.9% methylcellulose (Fluka Biochemica, Bucks, UK). 30% fetal calf serum (FCS), 10% BSA, 2% sodium bicarbonate, 5 X IO-' mol/L ~-mercaptwthanol, 2 IU erythropoietin. and 500 ng/mL granulocyte-macrophage colonystimulating factor (GM-CSF). The dishes were incubated at 37°C in humidified 5% CO2 in air for 14 days. Individual colonies were picked using sterile glass pipettes, resuspended into 50 pL of water, and boiled at 95°C for 8 minutes. A total of 12.5 pL of this suspension was added to microsatellite PCR reagent mixture to a final volume of 25 pL and processed as outlined above.
RESULTS
In MPDs and MDSs, chromosomal abnormalities observed in bone marrow metaphases can also be detected by The clinical details of the patients are shown in Table 1 . Four patients presented with a MDS, three with PRV, and the last patient with an unclassified MPD. All patients had a 2Oq deletion detected by conventional G-banding in at least 75% of bone marrow metaphases. We have previously defined two broad classes of 2Oq deletion14: small deletions in which the proximal G(+) band of 2Oq is missing and large deletions in which both G(+) bands on 20q are missing. Three of the patients reported here had a small deletion and two had a large deletion (Table 1 and Fig l) . In the three remaining patients, banding analysis was performed elsewhere and data on the deletion size were not available.
Microsatellite PCR analysis of peripheral blood granulocytes. Highly purified peripheral blood granulocytes and T cells were obtained as described in the Materials and Methods. Microsatellite PCR was then performed using 15 primer pairs from chromosome 20q (Fig 2) . Twelve of the primer pairs were chosen from within the common deleted region that we have previously defined on 2Oq." The remaining three primer pairs (D20S 100, D20S102, and PCKI) were chosen to represent a more telomeric region that has been reported to be deleted in one patient with AML2"
The results are shown in Table 2 I D20S55 I D20S43 D20S16 locus using DNA from both granulocytes and T cells. Moreover, the relative intensity of the 2 alleles was similar in both granulocytes and T cells from each patient, an observation that argues against the presence of a substantial subpopulation of granulocytes carrying the deletion. By contrast T-cell DNA from patient 8 gave rise to two alleles but granulocyte DNA only gave rise to a single allele. These results show that a 20q deletion was present in the granulocytes derived from patient 8 but was not detected in the granulocytes from patients l through 7.
FISH analysis of 209 deletions. The failure to detect molecular evidence of 20q deletions in granulocytes contrasted with the presence of an apparent 20q deletion in the vast majority of G-banded metaphases. FISH was therefore used to confirm the loss of chromosomal material in a patient with a large deletion (patient 3) and in a patient with a small deletion (patient 2; Table 3 and Fig 4) . Three cosmids from separate loci within the common deleted region (PLCI, ADA, and PPGB) were hybridized to bone marrow metaphases along with a chromosome 20 centromeric probe as a hybrid-+- Sensitivity of microsatellite PCR for detection of deletions. To assess the ability of microsatellite PCR to detect a small subpopulation of cells carrying a 20q deletion, mixing experiments were performed (Fig 5) . Cells from a clonal cell line carrying a 20q deletion (KS7) were mixed in varying proportions with cells from a cytogenetically normal cell line (KSIO) derived from the same patient. The resultant DNA mixtures were amplified in six independent experiFor personal use only. on October 22, 2017. by guest www.bloodjournal.org From Abbreviations: 1, one allele was detected at an informative locus; 2, two alleles were detected at an informative locus; U, uninformative;
ND, not done.
Results assessed by densitometry (see text). All other results were assessed by visual inspection of autoradiographs (see Fig 3 for examples).
ments using a primer pair from a locus within the 20q deletion (D20S176). Densitometric analysis of the results showed that the intensity of the upper allele exhibited a linear relationship with the percentage of cytogenetically normal cells. Visual inspection of the autoradiograph suggested that the relative intensity of the upper allele was detectably reduced in the presence of 40% cells carrying the deletion (Fig 5A) . Moreover, densitometric analysis could reproducibly detect even the presence of 20% cells carrying the deletion (Fig 5B) . These results were confirmed using a second primer pair from a different locus (D20S119) within the 20q deletion (data not shown).
To search for minor subpopulations of granulocytes carrying a 20q deletion, densitometric analyses of the microsatellite PCR results were performed ( Table 2 ). The results Patient 2 obtained at 3 loci with well separated alleles were analyzed in each patient. In patients 3 and 7, one allele was consistently less intense than the other in granulocytes compared to T cells. The allele ratios (less intense allele/more intense allele) obtained using granulocyte DNA from patient 3 were 0.64,0.66, and 0.69 (mean, 0.66) of the corresponding ratios obtained with T cell DNA; in patient 7, the granulocyte allele ratios were 0.68, 0.73, and 0.73 (mean, 0.71) of the corresponding T-cell allele ratios (see Table 2 for details of the loci studied). However, in the other 5 patients, the allele ratio obtained using granulocyte DNA was never reproducibly less than 80% of the ratio obtained using T-cell DNA from the same patient. These data therefore suggest that, in patients 3 and 7, the peripheral blood granulocytes contained a minor subpopulation carrying the 20q deletion but that the granulocytes of the remaining five patients did not contain a substantial subpopulation of cells carrying the 20q deletion. However, our results do not exclude the possibility that a minor subpopulation of granulocytes (<20%) was carrying the deletion in these patients.
Clonality of peripheral blood granulocytes.
Some patients with MPDs and MDSs have been reported to have polyclonal granulocytes, as assessed by the analysis of X
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For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From linked polymorphism~.~~ We therefore wondered whether the peripheral blood granulocytes that lacked the chromosome 20 deletion might represent polyclonal granulocytes derived from normal progenitors.
To address this possibility, the HUMARA assay3" was used to study the clonality of highly purified peripheral blood granulocytes and T cells (Fig 6) . To control for skewed lyonization, the ratio of PCR products obtained from granulocyte DNA after predigestion with Hha I was compared with the results obtained using T-cell DNA from the same patient. It has previously been shown that T cells represent the most appropriate source of control DNA:' possibly because the timing of X inactivation varies in different tiss u e~.~~ DNA derived from a clonal cell line was included in each experiment to control for Hha I enzyme activity. In each of the four female patients studied, predigestion with Hha I resulted in preferential amplification of a single allele from granulocyte DNA, whereas T-cell DNA gave rise to amplification of both alleles. These data show that the vast majority of granulocytes, but not T cells, obtained from all four female patients were clonally derived and therefore part of the malignant clone. Moreover, these results represent the first demonstration that chromosome 20 deletions may arise as a secondary event in patients with pre-existing clonal granulopoiesis.
Cytogenetic analysis rejected the prevalence of the 209 deletion in bone marrow cells. The results presented above showed that some patients with a 2Oq deletion in most of their bone marrow metaphases had clonal granulocytes in which a 20q deletion could not be detected using microsatellite PCR. The most likely explanation was felt to be preferential proliferation of cells canying the deletion during the generation of metaphases. The presence of the deletion in only a small minority of bone marrow cells would be consistent with the absence of the deletion in most peripheral blood granulocytes.
This hypothesis predicts that microsatellite PCR of whole bone marrow would not readily detect the deletion but in- stead would give a pattern similar to peripheral blood granulocytes. Bone marrow samples were available from patients 2, 3, and 8. We therefore scraped a small area of cells from bone marrow aspirate slides prepared from these patients. Microsatellite PCR was performed and the results are shown in Fig 7. As expected, the deletion was clearly detectable in peripheral blood granulocytes and bone marrow from patient 8. By contrast, although the deletion was not visible in peripheral blood granulocytes from patient 3, it was readily detected in bone marrow in two independent PCR reactions, with only a very faint signal for the lower allele. Densitometric analysis suggested that the deletion was present in 95% of bone marrow cells, whereas cytogenetic analysis had found the deletion in 12 of 12 metaphases. Similar results were obtained using bone marrow aspirate slides prepared from patient 2 (data not shown). In this case, densitometric analysis suggested the deletion was present in 75% of bone marrow cells, whereas cytogenetic analysis had found the deletion in 10 of 11 metaphases.
The 209 deletion was present in both erythroid and granulocyte/monocyte progenitors. Our data therefore showed that cytogenetic analysis did reflect the prevalence of the 20q deletion in bone marrow cells. This argued against the preferential proliferation of cells carrying the deletion. We therefore investigated an alternative possibility, ie, that the 20q deletion may have arisen in a lineage-restricted progenitor, unable to give rise to granulocytes, but committed to one or more other lineages (eg, erythroid). This seemed particularly plausible given the predominantly erythroid phenotype of the diseases present in six of the seven patients (Table 1) .
To address this issue, microsatellite PCR was used to assess the presence or absence of the 20q deletion in DNA from individual erythroid and granulocytehonocyte colonies. Peripheral blood mononuclear cells from patient 3 were cultured at low density in methyl cellulose. After 2 weeks, individual colonies were selected and DNA extracted from them. Using D20S197 and PLC1 primers, a 20q deletion 
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was detected in 10 of 18 colony-forming unit-granulocytemacrophage (CFU-GM) and 7 of 18 burst-forming unit-erythroid (BFU-E; Fig 7A) . These results clearly show that, in patient 3, the 2Oq deletion arose in a progenitor that was capable of giving rise to granulocytes and monocytes as well as erythroid cells. These data strongly suggest that the absence of the deletion in most peripheral blood granulocytes did not reflect lineage restriction of progenitors carrying the deletion, but instead resulted from other selective influences such as preferential retentioddestruction of granulocytes carrying the deletion within the bone marrow.
DISCUSSION
We show here the presence of a 20q deletion in bone m m w metaphases from patients with myeloid disorders but a failure to detect the deletion in peripheral blood granulocytes. These observations were surprising in view of previous results from this laboratory and other groups, which have readily shown chromosome deletions in peripheral blood granulocytes using both Southern blotting and microsatellite FCR.'5~'y.2627 Furth ermore, microsatellite PCR has detected a 5q deletion in peripheral blood granulocytes, even when the deletion was only found in 50% of bone marrow metaphases?' We have therefore investigated the molecular basis for the apparent absence of the 20q deletion from peripheral blood granulocytes in seven patients with either an MDS or an MPD.
Chromosome 20 is a small chromosome and deletions can be very difficult to detect by Giemsa banding analysis alone. To confirm the presence of a deletion, samples from two patients were further studied by FISH using three cosmids that map within a previously defined common deleted region.I5 In each case, the abnormal chromosome was unequivocally shown to have lost genetic material. We then assessed the possibility that a small subpopulation of granulocytes might carry the 20q deletion but be masked by the presence of granulocytes with no deletion. This would be reminiscent of our previous finding that a 20q deletion may arise in a cell capable of giving rise to B cells even though microsatellite PCR analysis of purified peripheral blood B cells did not detect the deletion." Mixing experiments were therefore performed to determine the sensitivity of the microsatellite PCR method for the detection of subpopulations of cells carrying a 20q deletion. These results showed that visual assessment of microsatellite PCR results could detect a deletion if it were present in ~4 0 % of cells. Moreover densitometric analysis could detect a deletion if it were present in more than 20% of cells, but would be unlikely to detect a deletion present in a smaller subpopulation of cells. Subsequent densitometric analysis of microsatellite PCR results from patient samples showed that the deletion was absent from most peripheral blood granulocytes in all seven patients.
The use of X-linked polymorphisms has shown that nucleated peripheral blood or bone marrow mononuclear cells usually appear clonal in patients with MDSs or MPDS.''"" Although granulocytes have been clonal in most patients in whom purified cell types have been studied, polyclonal granulocytes have been reported in a minority of patients." We therefore considered the possibility that our inability to detect 20q deletions in the peripheral blood granulocytes of the patients presented here might also have reflected the presence of polyclonal granulocytes derived from normal progenitors in these patients. However, in all four of the female patients presented here, the HUMARA assay showed that peripheral blood granulocytes were clonal, whereas T cells were polyclonal. Our results therefore strongly suggest that, in each of these patients, the vast majority of the granulocytes were derived from a neoplastic clone, and yet the 20q deletion was not observed in the granulocytes using microsatellite PCR. These observations are reminiscent of the suggestion that chromosomally normal B cells may be clonally derived in chronic myeloid leukemia.'' However, Fialkow et al" based their conclusions on analysis of EBVtransformed lymphoblastoid cell lines and not on studies of purified peripheral blood B cells.
Selective proliferation of progenitors carrying chromosome abnormalities has been invoked to explain discrepancies between G banding or metaphase FISH and interphase FISH that have been reported previously in a small number of patient^.'^.?^ These investigators have all reported occasional patients with a cytogenetic abnormality in the majority of bone marrow metaphases but detectable only in a minority of interphase nuclei. The difficulty with interpreting most of these reports stems from the lack of information about the nature of the interphase cells. In at least some cases it is clear that the interphase cells include a significant proportion of nondividing lymphoid cells that would not be expected to carry the chromosome abnormality. However, in view of these previous studies, we considered the possibility that progenitors carrying the 20q deletion may proliferate preferentially during the period of culture required to generate metaphases. Microsatellite PCR analysis of whole bone marrow from two patients clearly showed that the deletion was present in the majority of bone marrow cells and was completely consistent with the cytogenetic analysis. These results show that the cytogenetic studies were not merely detecting an unrepresentative subpopulation of cells with a 20q deletion.
In patients with MDS, deletions of chromosomes 5 and 7 have been show in granulocytes and monocytes but not in lymphoid ~e l l s . '~~*~~*~ These observations have given rise to the suggestion that some chromosome abnormalities associated with MDS may arise as secondary events in lineagerestricted progenitors. Because most of our patients had disorders with a prominent erythroid component, it was important to investigate the possibility that the 20q deletions may have arisen in a progenitor that was unable to differentiate into granulocytes but competent to give rise to other nonlymphoid lineages and especially to erythroid cells. Peripheral blood mononuclear cells derived from patient 3 were therefore grown in methylcellulose and microsatellite PCR was used to show the presence of the 20q deletion in a proportion of both CFU-GM and BFU-E. These data show that, in this patient, the 20q deletion had arisen in a progenitor capable of giving rise to both granulocyteshonocytes and erythroid cells, a result that strongly suggests that the absence of the deletion in most peripheral blood granulocytes did not reflect lineage restriction of progenitors carrying the deletion. Instead, we speculate that granulocytes carrying the deletion may be preferentially retained and/or destroyed in the bone marrow, thus giving rise to an overrepresentation of cytogenetically normal granulocytes in the peripheral blood. Our findings accord well with a recent report that showed high rates of intramedullary apoptotic death in patients with myelodysplasia.'* Our data suggest that, in some patients, apoptosis may preferentially affect chromosomally abnormal cells.
The ability to detect the deletion within individual colonies also allowed molecular mapping of the extent of the deletion. In this patient, loss of heterozygosity was demonstrated for markers D20S 174, D20S 16, and D20S I76 (data not shown) and the region of allele loss in this case was therefore more extensive than our previously determined common deleted region.'' However, this approach will increase the number of deletions that it is possible to map using microsatellite PCR and should help refine the common deleted region.
The results presented here have three important implications. Firstly, to our knowledge, they represent the first demonstration that a chromosome 20 deletion may arise as a secondary event in patients with pre-existing clonal granulopoiesis. It is clear that, in some patients, chromosome 20 deletions may arise during the evolution of MPDs or deletion to the malignant clone, as defined by X-linked polymorphisms, has not previously been established. Although the visible deletion appears to be a late event in the patients presented here, it should be emphasized that our data do not exclude the possibility that mutation of a critical gene on the "normal" chromosome 20 may be an early event in these disorders. Secondly, our data show the presence of a 20q deletion in the vast majority of bone marrow metaMDSs.s.9.11.1' However, the relationship of cells carrying the
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phases, and yet its absence in a majority of clonally derived peripheral blood granulocytes. Moreover, our results suggest that the most likely explanation for this discrepancy is selective destructionhetention within the bone marrow of granulocytes carrying the 20q deletion. Thirdly, our findings suggest that, in at least some patients with MPD and MDS, molecular analysis of peripheral blood granulocytes may not reflect the size of chromosomally abnormal clones present in the bone marrow.
